Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: Research: Forums: Virtual Conferences
1998 Society of Neuroscience Meeting

back to News

Enhancement of pathology in PS1/APP Tg mice via energy deprivation

by Brian J. Cummings

11 November 1998. There have been several reports over the years that the AD brain exhibits deficits in energy metabolism. In 1994, Yankner's group reported that sodium azide treatment increased the processing of APP to potentially amyloidogenic fragments in culture. Paul Jantzen and colleagues report (abstract 592.7) on the effects of NaAz administrationin PS1/APP (Duff/Hsiao) mice. Following 4 weeks of administration of NaAz (via subcutaneous infusion pump), they found that cytochrome oxidase activity was reduced by 22%. In untreated double Tg mice, they see relatively few activated microglia (detected with F480) associated with Abeta deposits, but in the NaAz treated animals, there is an extensive upregulation of microglia around Abeta deposits. The group did not report an increase in microglia associated with Abeta deposits in untreated Tg animals, in contrast to other studies. However, the association of activated microglia in the NaAz treated animals mirrored that typically seen in moderately severe AD cases, and was more extensive than I've seen in any transgenic model. Also, they reported the presence of TUNEL-positive nuclei in the NaAz treated Tg mice, while infusion of NaAz into non-Abeta depositing littermates did not active microglia nor result in significant numbers of TUNEL positive nuclei. Presumably, these littermates were nontransgenic, but this was not clear from the presentation. Jantzen did not present data addressing whether NaAz treatment actually leads to greater deposition of Abeta itself, as one might predict. It is encouraging that many labs are now moving to phases where different systems within these Tg models are challenged (e.g., see also abstract 592.6).




Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2012 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad